← Back to Search

Behavioural Intervention

vBloc (Active Device) for Obesity (ReCharge Trial)

N/A
Waitlist Available
Led By Charles Billington, M.D.
Research Sponsored by ReShape Lifesciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

ReCharge Trial Summary

The study evaluated the safety and efficacy of the vBloc Therapy delivered by the Maestro Rechargeable System compared to a sham control for the treatment obesity. The Maestro Rechargeable System delivers intermittent, electrical blocking signals to the anterior and posterior trunks of the intra-abdominal vagus nerve (termed vBloc Therapy) and is designed to reduce sensations of hunger and produce satiety leading to weight loss. After approval from the institutional review board, subjects provided written consent and were randomized in a 2 to 1 allocation to vBloc group (with laparoscopic placement of the leads and neuroregulator) or the sham group (placement of a custom sham neuroregulator only) on double-blinded basis. Both groups received similar diet and exercise counseling. Weight, adverse events, clinical laboratories, ECGs, eating questionnaires and quality of life data were evaluated throughout the 12 month study duration.

ReCharge Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage Responder Rate in the Treatment Arm.
Percentage of Excess Weight Loss (EWL) by Body Mass Index (BMI) Method.
Percentage of Subjects Experiencing Implant/Revision Procedure, Device or Therapy Related Serious Adverse Events (SAEs).

ReCharge Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: vBloc (Active Device)Active Control1 Intervention
The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period
Group II: Sham (Non-active Device)Placebo Group1 Intervention
The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period

Find a Location

Who is running the clinical trial?

ReShape LifesciencesLead Sponsor
10 Previous Clinical Trials
1,176 Total Patients Enrolled
8 Trials studying Obesity
1,047 Patients Enrolled for Obesity
Charles Billington, M.D.Principal InvestigatorUniversity of Minnesota
Michael Sarr, M.D.Principal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~17 spots leftby Apr 2025